Companies / Septerna, Inc.
Septerna, Inc.
Nasdaq: SEPNCIK 1984086SOUTH SAN FRANCISCO, CA
Financials · FY2025
Ownership
46.7M shares outstanding · as of Aug 5, 2026
Ownership
| Insiders | 0.37% | 175,002 |
| Institutions | 99.94% | 46,649,446 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 14
View all →| Insider | % of shares | Shares |
|---|---|---|
Bhatt ElizabethPresident and COO | 0.37% | 174,209 |
Shaikhly SamiraChief People Officer | <0.01% | 793 |
Finer JeffreyCEOChief Executive Officer · Director | — | — |
Kim Jae B.Chief Medical Officer | — | — |
Klein UweSVP, Biological Sciences | — | — |
Kolchinsky PeterDirector · 10% owner | — | — |
Labrucherie Gil MChief Financial Officer | — | — |
Long Daniel D.SVP, Drug Discovery | — | — |
RA Capital Healthcare Fund LPDirector · 10% owner | — | — |
RA Capital Management, L.P.Director · 10% owner | — | — |
Institutional holders 130
View all →| Holder | Value | % of shares |
|---|---|---|
| $173.29M | 13.32% | |
| $168.11M | 14.99% | |
| $134.09M | 10.30% | |
| $117.42M | 9.02% | |
| $87.80M | 6.75% | |
| $75.70M | 5.82% | |
| $64.71M | 4.14% | |
| $55.76M | 4.28% | |
| $42.05M | 3.23% | |
| $37.29M | 2.87% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | New | Common Stock | $21.33M | +891K | 890,754 1.91% of shares | medium |
| Q1 2026 as of | Perceptive Advisors LLC 13F manager | Exit | Common Stock | $-12.08M | -433K -100.00% | — | medium |
| Q1 2026 as of | Bvf INC/IL 13F manager | Trim | Common Stock | $-8.83M | -368K -21.36% | 1,353,249 2.90% of shares | medium |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | Add | Common Stock | $5.60M | +233K +6527.81% | 236,679 0.51% of shares | medium |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Trim | Common Stock | $-4.50M | -187K -82.44% | 39,840 0.09% of shares | low |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common Stock | $4.38M | +131K +7.26% | 1,932,088 4.14% of shares | low |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common Stock | $3.77M | +113K +20.85% | 652,630 1.40% of shares | low |
| Q1 2026 as of | Hussman Strategic Advisors, Inc. 13F manager | New | Common Stock | $2.52M | +105K | 105,000 0.22% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Biotechnology Value Fund L P | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| SEPN | Common Stock | 81734D104 |